COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,878 Articles (22,568 medRxiv, 8,310 bioRxiv)

Most recent first Previous |  Page 1977: Articles 19761-19770  | Next

A Healthy Buildings Guideline for the COVID-19 Pandemic and Beyond
Federspiel, C.
10.1101/2020.11.30.20241406 — Posted: 2020-12-02
International observational survey of the effectiveness of personal protective equipment during endoscopic procedures performed in patients with COVID-19
Niikura, R., Fujishiro, M., Nakai, Y., Matsuda, K., Kawahara, T., Yamada, A., Tsuji, Y., Hayakawa, Y., Koike, K.
10.1101/2020.12.01.20240853 — Posted: 2020-12-02
The role of population structure when measuring COVID-19 impact across countries
Bramajo, O., Infantino, M., Unda Venegas, R., Cardona-Maya, W. D., Richly, P.
10.1101/2020.11.30.20239947 — Posted: 2020-12-02
Racial disparities in COVID-19 mortality across Michigan, United States
Parpia, A. S., Pandey, A., Martinez, I., El-Sayed, A. M., Wells, C. R., Myers, L., Duncan, J., Collins, J., Fitzpatrick, M. C., Galvani, A. P.
10.1101/2020.11.30.20241133 — Posted: 2020-12-02
COVID-19 prevalence in 161 countries and over time
Louca, S.
10.1101/2020.12.01.20241539 — Posted: 2020-12-02 Discussion: Onsite
Smart Investment of Virus RNA Testing Resources to Enhance Covid-19 Mitigation
Gorji, H., Arnoldini, M., Jenny, D. F., Hardt, W.-D., Jenny, P.
10.1101/2020.11.30.20239566 — Posted: 2020-12-02
Serological prevalence of SARS-CoV-2 infection and associated factors in health care workers in a "non-COVID" hospital in Mexico City
Cruz-Arenas, E., Cabrera-Ruiz, E., Laguna-Barcenas, S., Colin-Castro, C. A., Chavez, T., Franco-Cendejas, R., Ibarra, C., Perez-Orive, J.
10.1101/2020.11.30.20241331 — Posted: 2020-12-02
Social network-based strategies for classroom size reduction can help limit outbreaks of SARS-CoV-2 in high schools. A simulation study in classrooms of four European countries.
Kaiser, A. K., Kretschmer, D., Leszczensky, L.
10.1101/2020.11.30.20241166 — Posted: 2020-12-02
A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
Kumar, S., de Souza, R., Nadkar, M., Guleria, R., Trikha, A., Joshi, S. R., Loganathan, S., Vaidyanathan, S., Marwah, A., Athalye, S. N.
10.1101/2020.12.01.20239574 — Posted: 2020-12-02 Discussion: Onsite
Convalescent Plasma in COVID-19. Mortality-Safety First Results of the Prospective Multicenter FALP 001-2020 Trial
gazitua, r., Briones, j. l., Selman, C., Villarroel-Espindola, F., Aguirre, A., Gonzalez-Steigmaier, R., cereceda, K., Mahave, M., Rubio, B., Ferrer-Rosende, P., Sapunar, J., Marsiglia, H., Morales, R., Yarad, F., Balcells, M. E., Rojas, L., Nervi, B., Nien, J. K., Garate, J., Prieto, C., Palma, S., Escobar, C., bascunan, J., Munoz, R., Pinto, M., Cardemil, D., Navarrete, M., Reyes, S., Espinoza, V., Yanez, N., Caglevic, C.
10.1101/2020.11.30.20218560 — Posted: 2020-12-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).